Skip to Main content Skip to Navigation
Journal articles

Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.

Abstract : Hsp90 is an ATP-dependent chaperone known to be overexpressed in many cancers. This way, Hsp90 is an important target for drug discovery. Novobiocin, an aminocoumarin antibiotic, was reported to inhibit Hsp90 targeting C-terminal domain, and showed anti-proliferative properties, leading to the development of new and more active compounds. Consequently, a new set of novobiocin analogs derived from 1,6-naphthyridin-2(1H)-one scaffold was designed, synthesized and evaluated against two breast cancer cell lines. Subsequently, cell cycle progression and apoptosis were conducted on best candidates, finally Western Blot analysis was performed to measure their ability to induce degradation of Hsp90 client proteins.
Document type :
Journal articles
Complete list of metadata

Cited literature [31 references]  Display  Hide  Download
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Monday, June 20, 2016 - 12:05:52 PM
Last modification on : Wednesday, April 27, 2022 - 3:57:47 AM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document



David Montoir, Sophie Barillé-Nion, Alain Tonnerre, Philippe Juin, Muriel Duflos, et al.. Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.. European Journal of Medicinal Chemistry, Elsevier, 2016, 119, pp.17-33. ⟨10.1016/j.ejmech.2016.04.050⟩. ⟨inserm-01334013⟩



Record views